Actavis sells off Chinese subsidiary


Generic drugs heavyweight Actavis is selling off a subsidiary based in Foshan, China. The business is being bought by Zhejiang Chiral Medicine Chemicals for an undisclosed sum.

In a company statement, Actavis stressed that the company ‘intends to continue further commercial operations in China in collaboration with its preferred business partners’. But in an interview with Bloomberg, chief executive Paul Bisaro claimed that doing business in China is ‘too risky’, and the returns were not worth the effort compared to other markets.


Related Content

UCB sells speciality generics subsidiary

26 November 2014 Business

news image

Firm will use $1.5bn proceeds to reduce debt and concentrate on developing new drugs in neurology and immunology

Riding new waves

6 January 2015 Business

news image

Pharmaceutical industry roundup of 2014

Most Read

Mystery of coloured water droplets that chase and repel each other solved

19 March 2015 Research

news image

Discovery could herald sprays that hoover up dirt and keep solar panels clean

Simple cooking changes make healthier rice

23 March 2015 Research

news image

Adding oil to water, cooling and reheating rice makes fibre-like resistant starch, reducing calories

Most Commented

Worrying molecule found in bottled water

9 September 2013 Research

news image

Analysis finds a new endocrine disrupting chemical in bottled water

Impatient chemistry

28 February 2014 Last Retort

news image

Is the pressure to publish making chemists cut corners?